Point/Counterpoint: Is It Time for Universal Germline Genetic Testing for All GI Cancers?
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333
Informations de publication
Date de publication:
20 08 2022
20 08 2022
Historique:
pubmed:
2
6
2022
medline:
20
8
2022
entrez:
1
6
2022
Statut:
ppublish
Résumé
Use of germline genetic testing among patients with cancer is increasing because of (1) the availability of multigene panel tests that include multiple cancer susceptibility genes in a single test, (2) decreased costs of these tests and improvements in insurance coverage, and (3) US Food and Drug Administration-approval of genotype-directed therapies such as poly(ADP-ribose) polymerase inhibitors for individuals with certain cancers and pathogenic germline variants in
Identifiants
pubmed: 35649230
doi: 10.1200/JCO.21.02764
doi:
Substances chimiques
Poly(ADP-ribose) Polymerase Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM